SHP Shire

TIDMSHP 
 
   Shire to announce third quarter 2018 results 
 
   Dublin, Ireland -- October 18, 2018 -- Shire plc (LSE: SHP, NASDAQ: 
SHPG), will announce third quarter 2018 earnings on Thursday November 1, 
2018. 
 
 
 
 
Results press release will  12:00 GMT / 08:00 EDT 
 be issued at: 
Investor conference call    14:00 GMT / 10:00 EDT 
 time: 
 
   Live conference call for investors: 
 
   Flemming Ornskov, MD, M.P.H., Chief Executive Officer and Thomas 
Dittrich, Chief Financial Officer will host the investor and analyst 
conference call at 10:00 am EDT / 14:00 GMT. 
 
   The details of the conference call are as follows: 
 
 
 
 
UK dial in:           0800 358 9473 or +44 333 300 
                       0804 
US dial in:           1 855 857 0686 or 1 631 913 
                       1422 
International Access  Click here: 
 Numbers:             http://events.arkadin.com/ev/docs/NE_W2_TF_Events_International_A 
                      ccess_List.pdf 
Password/Conf ID:     28705371 # 
Live Webcast:         Click here 
                      http://investors.shire.com/presentations-and-reports/quarterly-re 
                      sults-and-presentations 
 
   Replay: 
 
   A replay of the presentation will be made available, subject to approval 
by the UK Takeover Panel, for two weeks by phone and for three months by 
webcast.  Replay information made available will be contained on the 
Investor Relations section of Shire's website at 
http://investors.shire.com/. 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Christoph Brackmann   christoph.brackmann@shire.com   +41 41 288 4129 
Sun Kim               sun.kim@shire.com               +1 617 588 8175 
Scott Burrows         scott.burrows@shire.com         +41 41 288 4195 
 
Media 
Katie Joyce           kjoyce@shire.com                +1 781 482 2779 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global biotechnology leader serving patients with rare 
diseases and specialized conditions. We seek to push boundaries through 
discovering and delivering new possibilities for patient communities who 
often have few or no other champions. Relentlessly on the edge of what's 
next, we are serial innovators with a diverse pipeline offering fresh 
thinking and new hope. Serving patients and partnering with healthcare 
communities in over 100 countries, we strive to be part of the entire 
patient journey to enable earlier diagnosis, raise standards of care, 
accelerate access to treatment, and support patients. Our diverse 
portfolio of therapeutic areas includes Immunology, Hematology, Genetic 
Diseases, Neuroscience, Internal Medicine, and Ophthalmics. 
 
   Championing patients is our call to action - it brings the opportunity - 
and responsibility - to change people's lives. 
 
   www.shire.com 
 
 
 
 

(END) Dow Jones Newswires

October 18, 2018 07:15 ET (11:15 GMT)

Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024

Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024